Jan. 15, 2013 (Shareholders Foundation) -- An investigation on behalf of investors of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares over potential securities laws violations by Amicus Therapeutics, Inc. and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Amicus Therapeutics, Inc. (NASDAQ:FOLD) concerning whether a series of statements by Amicus Therapeutics, Inc. (regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported that its annual Revenue rose from $0.92 million in 2010 to $21.43 million in 2011 and its Net Loss decreased from $54.94 million in 2010 to $44.41 million in 2011.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) grew from $2.10 per share in Nov. 2011 to as high as $6.78 per share in February 2012. Throughout 2012 NASDAQ:FOLD shares managed to trade for the most part above $5 per share.

Then on December 19, 2012Amicus Therapeutics and GlaxoSmithKline announced the results from the first phase 3 Fabry Monotherapy study.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) dropped from $5.97 on Dec. 18, 2012 to as low as $3.06 on Dec. 20, 2012 and continued to declined to as low as $2.53 per share on Dec. 26, 2012.

On Jan. 15, 2013, NASDAQ:FOLD shares closed at $4.19 per share.